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Abstract
Purpose The molecular chaperone heat shock protein 90
(HSP90) plays an important role in several types of tumors
also participating in the modulation of the activity of receptor
tyrosine kinases activity such as members of the Her family.
We evaluated the significance of HSP90 and Her2 expression
in colon cancer.
Methods HSP90 and Her2 expression was determined by
immunohistochemistry and by fluorescence in situ hybridiza-
tion (FISH) on 355 primary resected colon carcinomas.
Results were correlated with pathologic features (Union for
International Cancer Control (UICC) pTNM category, tumor
localisation, tumor differentiation), additional molecular ge-
netic characteristics (BRAF, KRAS mutational status, mis-
match repair genes (MMR)), and survival.
Results HSP90 immunoreactivity was observed in various
degrees. Fifty-one cases (14 %) were positive for Her2 (score
2+ and 3+) with 16/43 cases with Her2 2+ staining pattern
showing amplification of Her2 determined by FISH. There
was a significant correlation between high HSP90 expression
and Her2 overexpression (p=0.011). High HSP90 expression
was associated with earlier tumor stages (p=0.019), absence
of lymph node (p=0.006), and absence of distant metastases
(p=0.001). Patients with high tumoral HSP90 levels had a
better survival (p=0.032), but this was not independent from
other prognostic relevant pathologic parameters. Her2 expres-
sion was not associated with any of the investigated histopath-
ological, molecular, or clinical parameters.
Conclusions High HSP90 levels are reflecting lower malig-
nant potential in colon cancer. Her2 positivity can be observed
in a small number of cases. Targeting HSP90 and/or Her2 may
be an alternative therapeutic approach in colon cancer in a
subset of patients.
Keywords HSP90 . Her2 . Immunohistochemistry . Colon
cancer
Introduction
A significant number of gastric and gastroesophageal adeno-
carcinomas shows amplification and overexpression of Her2
[1, 2] leading to the introduction of anti-Her2-directed therapy
with trastuzumab in the treatment of metastatic adenocarci-
nomas of the esophagogastric junction and the stomach [3, 4].
In contrast to adenocarcinomas of the upper gastrointestinal
tract, studies about Her2 in colorectal cancer are less compre-
hensive, and the studies show a high variability of Her2
positivity rates in these tumors [5–12].
Her2 has been shown to interact with HSP90, a molecular
chaperone belonging to the group of heat shock proteins.
These molecules are responsible for the correct folding of
proteins, prevention of protein aggregation, and protein acti-
vation [13, 14]. There are data which suggest that HSP90
expression may also support the effects of oncogenic Her2
[15] which represents a potential mechanism of resistance to
Her2-directed drugs. On the other hand, HSP90 inhibitors,
which have been developed recently, may potentiate the
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effects of anti-cancer drugs targeting client proteins of HSP90
[16]. The relationship between HSP90 and Her2, however,
has not been investigated so far for colon carcinomas.
Moreover, there are currently only scarce data about HSP90
expression in human colon cancer tissue [17, 18].
The aim of the present study was to investigate the role of
Her2 in colon cancer and to get deeper insights of tumor
biology and behavior regarding Her2-positive carcinomas.
We furthermore investigated any possible relationship of
Her2 and HSP90 as potentially targetable molecules in colon
cancer.
Materials and methods
Patients and tissues
We investigated formalin-fixed and paraffin-embedded
(FFPE) archival cancer tissue from 355 patients with colon
carcinoma who underwent surgery between 1993 and 2005 at
the Klinikum Rechts der Isar of the Technische Universität
München (Germany). All patients had a primary resection.
Informed consent for the use of additional molecular analysis
was given at the time of surgery, and the use of archival tissue
for molecular analysis was approved by the local ethical
commission (No. 2136/08). Follow-up data (overall survival)
were available for 349 patients.
Immunohistochemistry
Immunohistochemistry was performed on FFPE tissue on a
tissue microarray (TMA) as described before [19].
Representative tumor sections were marked, and two core
needle biopsy specimens of 1.0 mm in diameter were retrieved
and placed in a recipient wax block using a manual arrayer
(Beecher Instruments; Sun Prairie, Wisconsin, USA). For a
subset of cases (n=17), where additional lymph node metas-
tases were investigated, full slide sections were used (see
below).
The paraffin blocks were freshly cut (3 μm). Slides were
dewaxed and rehydrated, with subsequent heat-induced anti-
gen retrieval using 10 mM citrate buffer (pH 6), H2O2
blocking using 3 % H2O2 in aqua dest., and avidin/biotin
blocking (avidin/biotin blocking kit; Vector Laboratories,
Inc., Burlingame, CA, USA). The sections were then incubat-
ed with antibodies for HSP90 (1:50; Abcam, Cambridge,
UK), which recognizes both alpha and beta isoforms of
HSP90, Her2 (1:300; DAKO, Glostrup, DK), and for
MLH1, MSH6, MSH2, and PMS2 (1:200, 1:200, 1:1,600,
and 1 :75 , respec t ive ly ; a l l Le ica Novocas t ra ) .
Immunodetection was performed with the Dako REAL™
Detection System Peroxidase/DAB+kit (DAKO, Glostrup,
DK)which resulted in a brown staining. A breast cancer tumor
sample with known Her2 status (immunohistochemistry
(IHC) 3+ and high-level amplification) and high HSP90 ex-
pression served as positive control. For negative controls,
staining without the primary antibody was performed.
Her2 expression was assessed according to published rec-
ommendations for Her2 evaluation in gastric carcinoma [20],
and we used the criteria for assessment of Her2 on bioptic
tissue due to the tumor content of the TMA core which is
comparable to a biopsy. In short, immunohistochemistry 3+
staining was defined as strong complete basolateral or lateral
membranous staining of cell clusters irrespective of the per-
centage of tumor cells, visible at low magnification (×2.5–5);
immunohistochemistry 2+ was defined as weak to moderate
basolateral or lateral membranous staining visible at×10–20
magnification; and immunohistochemistry 1+ staining was
defined as weak membranous staining visible only with×40
magnification. Cases without visible membranous reactivity
were classified as negative (Fig. 1) All cases with Her2 score
2+ were additionally investigated by fluorescence in situ
hybridization (FISH) according to the criteria for assessment
of Her2 status by the FDA/European Medicines Evaluation
Agency (EMEA) for gastric cancer [20].
Expression of HSP90 (Fig. 2) was assessed by determina-
tion of cytoplasmic staining based on the intensity of immu-
nostaining and the percentage of stained tumor cells.
Immunostaining was scored as 0 (no immunostaining), 1
(weak immunostaining), 2 (moderate immunostaining), or 3
(strong immunostaining). The percentage of positive tumor
cells was scored as 0 (none), 1 (<10 %), 2 (10–50 %), 3 (51–
80 %), or 4 (>80 %). Multiplication of the scores for intensity
and percentage resulted in a staining index (SI) ranging from 0
to 12. Similar to a previous study [19], we then divided the
expression of HSP90 into low to moderate to high according
to the terciles of the distribution of SI.
Evaluation of mismatch repair (MMR) genes MLH1,
PMS2, MSH2, and MSH6 was performed following current
recommendations [21]. Every nuclear immunoreactivity was
regarded as positive. MMR deficiency was defined as a loss of
expression of at least one marker. All immunohistochemical
stainings were scored by two independent observers (KB, ED,
or RL), and discrepancies were discussed on a multihead
microscope with a final consent. Only cores with technically
unequivocal staining results and sufficient tumor content (>50
tumor cells) were used for final analysis.
Fluorescence in situ hybridization
All cases showing an immunohistochemical Her2 score of 2+
were also tested for Her2 amplification by FISH. An assay
with fluorescence-labeled locus-specific DNA probes for
Her2 and chromosome-17 centromeric α-satellite
(Chrombios) was hybridized onto 4-μm TMA sections as
described before [22]. FISH signal evaluation was performed
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by visual counting using an epifluorescence microscope
(Zeiss Axioplan 2, Carl Zeiss Microimaging GmbH). At least
50 invasive tumor cells per case with a minimum of one signal
for Her2 gene and centromere 17 were randomly selected, and
the mean Her2 and centromere 17 count was calculated. Cases
were classified as amplified when Her2/cep17 quotient was
≥2.
KRAS and BRAF analysis
Mutational analysis of KRAS and BRAF was performed on
all cases showing positive Her2 expression (score 2+ and 3+).
For this analysis, we used real-time PCR with high-resolution
melting analysis (HRMA) from genomic DNA as previously
described [23].
Statistical analysis
IBM SPSS 21.0 Statistics statistical software (SPSS, Inc.,
Chicago, IL, USA) was used for statistical analysis.
Associations between immunohistochemical staining pat-
terns, FISH analysis, and pathological features were given in
crosstabs and were evaluated with χ2 test. Kaplan-Meier
estimates, log rank tests, and Cox’s proportional hazards re-
gression analysis were used for survival analysis. All tests
were two-sided, and the significance level was set at 0.05.
Results
Patients and pathologic findings
One hundred fifty-five patients were female (44 %), and
200 of the patients were male (56 %). The mean age was
65±12 years (median, 66; range, 25 to 91). Mean follow-
up time for surviving patients was 87±27.6 months.
Complete tumor resection (R0) was achieved in 306 cases
(86.2 %). All tumors were reclassified according to the
current Union for International Cancer Control (UICC)
TNM classification [24]. Tumor grading was done accord-
ing to the WHO classifications of tumors of the digestive
system [25]. The pathologic characterization of the collec-
tive is given in Table 1. The postoperative UICC staging
of the tumors is given in Table 2.
Her2 expression and amplification in primary tumors
Of 355 cases, 185 tumors (52 %) showed no Her2 immu-
noreactivity, 119 tumors (34 %) had an immunoscore of
1+, 43 cases (12 %) showed 2+ immunoreactivity, and 8
cases (2 %) showed 3+. Sixteen cases with Her2 2+ were
found to have an amplification of Her2 using FISH.
Therefore, 24 cases (7 %) would have been classified as Her2-
“positive status” according to the criteria of the FDA/EMEA for
gastric cancer.
Fig. 1 Examples of
immunohistochemical stainings
for Her2 in primary resected
colon cancer. a Score 0
(negative). b Score 2+. c Score 3+
; ×20; brown membranous stain-
ing of tumor cells
Fig. 2 Examples of
immunohistochemical stainings
for HSP90 in primary resected
colon cancer. a Negative
expression. bModerate
expression. c High expression;
×20; brown cytoplasmic staining
of tumor cells
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HSP90 expression in primary tumors
Immunohistochemical analysis for HSP90 was successfully
applied on TMA cores of 353 tumors. For the remaining
cases, HSP90 expression could not be studied due to too less
amount of cells in the TMA cores. HSP90 expression was
negative/low in 96 cases (27 %), moderate in 152 cases
(43 %), and high in 105 cases (30 %).
Association between Her2 and HSP90
There was a correlation between high HSP90 expression and
Her2 expression. Her2-negative tumors more frequently had
low HSP90 expression levels, whereas the percentage of
Her2-positive tumors with high HSP90 expression was com-
parable with lower HSP90 levels. This was statistically sig-
nificant (p=0.011; Table 3 (a)). When using the gastric cancer
criteria for Her2 status, the association between HSP90 and
Her2 was not statistically significant anymore. However, only
15 cases would have fallen into this group of Her2-positive
cases (Table 3 (b)).
Her2 and HSP90 in lymph node metastases
Lymph node metastases of 17 cases (7 Her2-positive and 10
Her2-negative primary tumors) were additionally investigated
for Her2 and HSP90. Her2 status of the primary tumors and
the lymph node metastases correlated significantly with each
other (p=0.009), with 14/17 cases (82.3 %) showing concor-
dant results. Two cases were Her2 positive in the primary
tumor, but negative in the metastases. One case was Her2
positive in the lymph node metastasis, but negative in the
primary tumor. In addition, there was a correlation between
Her2 status and HSP90 expression (p=0.035) also in the
lymph node metastases.
Clinicopathological parameters and survival analysis
Her2 expression or amplification of the primary tumors was
not associated with pT category, presence of lymph node and
distant metastases, or tumor differentiation. Neither an asso-
ciation between Her2 and tumor localization (right sided vs.
left-sided carcinomas), MMR status, or survival (Table 4,
Fig. 3) was present. KRAS mutations of codon 12/13 were
detected in 51 % (26 cases) and BRAF mutation in 10 % (5
cases) of the Her2 IHC-positive cases, which is within the
range of the usual frequency of these alterations in colorectal
cancer. High HSP90 expression was associated with earlier
tumor stages (p=0.019), absence of lymph node (p=0.006),
Table1 Characterization
of the case collective or
primary resected colon
carcinomas
Parameter Number Percent
pT category
pT1 21 5.9
pT2 62 17.5
pT3 193 54.4
pT4 79 22.3
Lymph node metastases
Absent 215 60.6
Present 140 39.4
Distant metastases
Absent 299 84.2
Present 56 15.8
Grading
G1 3 0.8
G2 230 64.8
G3 118 33.2
G4 4 1.1
Total 355
Table 2 Postoperative UICC staging of the collective of primary resected
colon carcinomas
Postoperative UICC stage Number Percent
I 74 20.9
IIA 98 27.6
IIB 18 5.1
IIC 14 3.9
IIIA 8 2.3
IIIB 67 18.9
IIIC 21 5.9
IVAa 31 8.7
IVBa 24 6.8
Total 355 100.0
a Forty-three patients had liver metastases (HEP), 43 patients had perito-
neal metastases (PER), and 16 patients had metastases of other location;
among them, eight had pulmonary metastases (PUL)
Table 3 Correlation between (a) HSP90 expression and Her2 expression
(p=0.011) and (b) between HSP90 expression and Her2 status according
to the FDA/EMEA (p=0.58)
HSP90 expression Total
Negative Low High
(a) Her2 expression
Score 0/1+ 83 137 82 302
Score 2+/3+ 13 15 23 51
total 96 152 105 353
(b) Her2 status (FDA/EMEA)
Negative 86 145 98 329
Positive 10 7 7 24
Total 96 152 105 353
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and absence of distant metastases (p=0.001), but not with
tumor localization or MMR status (Table 5) Patients with high
tumoral HSP90 levels had a better survival compared to those
with negative or low expressing tumors (p=0.032; Fig. 4), but
this was not independent from other prognostic relevant path-
ologic parameters (Table 6).
Discussion
In the present study about Her2 and HSP90 in colon carcino-
mas, we demonstrate that elevated HSP90 expression can be
observed in a significant number of cases. It is associated with
lower malignant potential in these tumors. The small propor-
tion of tumors which showed Her2 positivity significantly
more frequently had also higher tumoral HSP90 expression
levels.
Her2 overexpression and amplification can be observed not
only in breast cancer but also in gastrointestinal tumors.
Numerous studies have investigated Her2 in malignancies of
the upper gastrointestinal tract, where Her2 overexpression
and amplification have been detected in significant numbers
of cases [1, 2]. Works on Her2 in colon and rectal carcinomas
have been published to a lesser degree and report a wide range
between 2% and up to over 40%Her2 positivity rates [5–12].
There is a considerable variability with regard to methodical
approaches (immunohistochemistry, RT-PCR, in situ hybrid-
ization) and interpretation of, e.g., immunohistochemical stain-
ing patterns of Her2 in colorectal carcinomas which may ac-
count for these diverging data. These inconsistencies are similar
to many studies on gastric cancer [1, 18]. In order to gain better
Table 4 Correlation between
Her2 expression and Her2 status
according to the FDA/EMEA and
pathological parameters
Parameter Her2 expression Her2 status (FDA/EMEA)
Score 0/1+ Score 2+/3+ p value Her2 negative Her2 positive p value
pT category
pT1 20 1 0.16 20 1 0.54
pT2 53 9 56 6
pT3 159 34 179 14
pT4 72 7 76 3
Lymph node metastases
Absent 260 39 0.23 201 13 0.77
Present 44 12 129 11
Distant metastases
Absent 260 39 0.08 280 19 0.32
Present 44 12 51 5
Grading
1 and 2 204 29 0.32 218 15 0.88
3 and 4 100 22 113 9
Tumor localization
Right 52 11 0.27 56 7 0.11
Left 252 40 275 17
MMR status
Loss 36 4 0.29 39 1 0.22
Present 268 47 292 23
Total 304 51 331 24
Fig. 3 No significant correlation of Her2 expression and survival in
colon cancer patients
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homogenization of Her2 testing on gastric carcinomas, a pro-
posal about standardization of immunohistochemical scoring
was recently published by the group of Rüschoff who also were
responsible for the Her2 diagnostics of the TOGA study [20].
Using these criteria, we could detect elevated membranous
Her2 immunoreactivity (i.e., scores 2+ and 3+) in 14 % of the
cases. However, if using the criteria for gastric carcinoma,
where Her2 positivity is defined as either IHC 3+ or IHC 2+
plus positive FISH, Her2 positive status was observed in only
7 %.
Using this algorithm, the rate of Her2-positive tumors was
recently reported to be 12 % of biopsies and in up to 27 % of
extensively investigated resected specimens in another study
on locally advanced rectal carcinomas which had been treated
by neoadjuvant radiochemotherapy [26]. Our collective
consisted of primary resected colon carcinomas of all stages,
and we found a lower rate of Her2-positive tumors. There was
no association between Her2 and relevant clinicopathologic
parameters such as pT category, presence of lymph node and
distant metastases, tumor localization, tumor differentiation,
MMR status, KRAS or BRAF mutational status, or survival.
Although we could not demonstrate any topographic differ-
ences when comparing right- to left-sided cancers, a site-
specific difference between colon and rectal cancer may con-
tribute to the difference in the rate of positive cases. However,
we found similar Her2 expression and amplification rates like
a previous study where the breast cancer scoring system had
been applied [10]. In a subset of cases, we were also able to
investigate the Her2 status in lymph node metastases.
Concordant to data from gastric cancer [27, 28], we found a
constant Her2 status in over 80 % of the cases. Similar to the
findings from gastric carcinomas, the reason for the discrepant
findings in these three cases may be either a true biological
phenomenon or due to a sampling bias.
We based our investigation on a tissue microarray where
we have to accept a certain amount of potentially false-
negative results due to intratumoral heterogeneity, because
small spots of overexpressing tumor areas may be missed in
the TMA cores [29]. To take this into account, we decided to
use the proposed modified criteria for Her2 testing on biopsies
[20], which have comparable size and tissue content as TMA
cores and which has a lower cutoff for the amount of cells
whose positivity defines the Her2 status.
Fig. 4 Significant better survival for colon cancer patients with high
tumoral HSP90 expression
Table 6 Multivariate analysis of prognostic relevant factors
Factor HR 95.0 % CI p value
pT category
(pT1 vs. pT2 vs. pT3 vs. pT4)
1.472 1.148–1.889 0.002
Lymph node metastases
(absent vs. present)
1.941 1.356–2.777 <0.001
Distant metastases
(absent vs. present)
4.927 3.310–7.335 <0.001
HSP90 expression
(negative/low vs. high)
0.894 0.604–1.324 0.57
Table 5 Correlation between HSP90 expression and pathological
parameters
Parameter HSP90 expression p value
Negative Low High
pT category
pT1 4 5 12 0.082*
pT2 15 28 19
pT3 56 79 57
pT4 21 40 17
Lymph node metastases
Absent 54 84 75 0.023**
Present 41 68 30
Distant metastases
Absent 71 128 98 0.001
Present 25 24 7
Grading
1 and 2 60 98 74 0.46
3 and 4 36 54 31
Tumor localization
Right 17 25 21 0.77
Left 79 127 84
MMR status
Loss 14 11 15 0.11
Present 82 141 90
Total 96 152 105
*p=0.019; **p=0.006, for high HSP90 expression vs. negative/low
expression
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Despite this limitation, TMA technology has been shown
to be a powerful tool for analyzing biomarkers in larger
sample collections [30]. For the purpose of an explorative
study, the relatively high number of cases and the advantages
of homogenous reaction conditions which avoid false-positive
or false-negative staining or hybridization results because of
technical reasons may equilibrate limitations regarding
intratumoral heterogeneity. Our approach seems to be appro-
priate for the purpose of an explorative study on the associa-
tion between Her2 and HSP90, which also included additional
immunohistochemical analysis, such as the analysis of mis-
match repair genes. For clinical practice, however, the analysis
of whole tissue sections should be favored since false-negative
results may generate wrong therapeutic consequences.
Elevated HSP90 expression levels could be detected in a
significant number of colon carcinomas with one third of
tumors showing high HSP90 expression. This was observed
mainly in tumors of lower stages and also associated with a
better outcome of the patients. Moreover, HSP90 expression
was significantly associated with Her2 expression and ampli-
fication. The biologic activity of Her2 is influenced and con-
trolled bymolecular chaperones such as members of the group
of heat shock proteins (HSPs). These molecules assist in the
maintenance of cellular integrity and homeostasis by assur-
ance of accurate folding of other proteins [13, 14].
Deregulated activity of HSPs has been found in malignant
diseases which may be due to intrinsic anti-apoptotic effects
but also to the altered interaction with other oncogenic mole-
cules [31, 32]. Recently, we could demonstrate that high
tumoral expression levels of HSP27 and HSP70 are associated
with negative outcome in colon cancer in the same case
collection as in the present study [19]. HSP90 is one of the
most abundant cellular HSPs. Besides the tyrosine kinases
Her2 and EGFR, other molecules such as AKT, RAF, and
RAS and mutated signaling proteins like p53 and v-Src have
been described to interact with HSP90 [33, 34]. This strong
association with oncogenes has evoked the interest on the
impact of molecular chaperones, especially HSP90 as poten-
tial anti-tumoral targets. In vitro HSP90 inhibitors enhanced
TRAIL-induced apoptosis in colorectal cancer cells via sup-
pression of survival signaling [35]. Blocking heat shock pro-
tein 90 inhibited the growth of human colon cancer cells and
improved the efficacy of oxaliplatin in p53-deficient colon
cancer tumors in a mouse model [36]. On the tissue level,
tumor HSP90α gene overexpression has been shown to be
correlated with metastases and poor prognosis in a study of 56
colorectal cancer patients [18]. This is in contrast to our
findings which were obtained by immunohistochemistry
and, on the protein level, generated from a much larger col-
lective of cases. Such discrepancies between gene and protein
expression data, however, are not infrequent since proteomic
and genomic information often does not correlate because of
different posttranslational modifications or protein turnover.
Recently, we have reported a strong correlation between
HSP90 and Her2 expression in gastric carcinomas which is in
line with the observations of the present study [37]. Similar
observations have also been made in vitro for breast and
gastric cancer, where data about overcoming Her2 resistance
by increasing HSP90 activity already exist [38]. Based on
these data, HSP90 may represent a potential targetable mole-
cule, and anti-HSP90 treatment alone or in combination with
other drugs may offer interesting alternative therapeutic op-
tions, especially in Her2-positive tumors [39, 40]. To the best
of our knowledge, there are currently no data about the co-
regulation of HSP90 and Her2 in colorectal cancer yet, so that
the present paper represents the first study which postulates an
association between Her2 and HSP90 expression on the tissue
level, in the primary tumors, and also in metastases. Although
higher HSP90 levels were observed with higher frequency in
the lower-stage groups, there still were a considerable number
of advanced cancers showing high HSP90 as well. Since
tumors of higher stages are more likely to have local or distant
relapses and are therefore treated by additional cytotoxic
regimes, anti-HSP90 treatment alone, or in combination with
Her2 targeting could represent an additional option.
In summary, we could demonstrate an increased immuno-
reactivity for Her2 and corresponding gene amplification in a
small subset of colon carcinomas. High HSP90 expression
levels were detected in a significant number of cases and were
associated with lower malignant potential in colon cancer. The
observed association between HSP90 and Her2 expression
may reflect a co-regulation of these molecules. Targeting
HSP90 and/or Her2 may therefore be an alternative therapeu-
tic approach in colon cancer in a subset of patients.
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